Two powerful and innovative cholesterol drugs are likely to approved this summer in the United States. Both drugs have many similarities, but one significant difference may be reflected in the pricing. Many analysts are expecting the lower dosage medication to be sold for a lower price. See more here. (Source: Deena Beasley, Reuters, 5/26/15)
You are here: / / How Competitive Could Dosage Based Pricing Get with New Cholesterol Drugs?